About us
Who We Are
A stellar compliance record following global standards

BioDuro-Sundia, an Advent International portfolio company is a trusted, leading contract research development, manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 10 global sites across 7 cities.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one stop shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Science-driven, customer-oriented, flexible, people focused culture enables us to provide top-tier integrated, fast and flexible tailored services to our customers to meet their unique needs and accelerate development timeline.

27
Years
Since Operation
~2,300
Active Projects
3,000
+
Staff Worldwide
1,500
+
Active Customers
10
Facilities Across 7
Cities Globally
Our Mission
To be the TRUSTED partner delivering world-class drug discovery,
development and manufacturing services
CORPORATE VALUES: ARTRI
ACCOUNTABILITY
We always take responsibility for our actions and behavior and conduct ourselves to established metrics of high performance.
RESPECT
We deeply respect our employees and clients, within a family structure, based on equality and understanding.
TENACITY
We know we may face adversity, but will never give up, but persevere to succeed.
RESULTS
We establish clear measures of success and deliver results to our internal and external stakeholders.
INTEGRITY
We are honest with ourselves and transparent in our actions and hold Intellectual Property (IP) standards at the highest level.
Global Presence
With focused centers of excellence in the
United States and China
Learn more
Management
Leadership Team
Chief Executive Officer
Kent M. Payne, PhD
Chief Executive Officer
Kent M. Payne, PhD

Dr. Kent M. Payne is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. Dr. Payne combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. In addition to the United States,he has also successfully led the geographic expansion of businesses into Europe, Asia, and South America. Dr. Payne currently serves as CEO for BioDuro-Sundia, LLC (an Advent International company) and also serves as a board member for Goodwin Biotechnologies (a Signet Healthcare company).

President, Drug Discovery
Xiang Li, D.Phil.
President, Drug Discovery
Xiang Li, D.Phil.
Dr. Xiang Li is currently President, Drug Discovery at BioDuro-Sundia, responsible for global drug discovery services at BioDuro-Sundia, including Discovery Chemistry, in vitro Discovery Biology, in vivo Pharmacology, Oncology, Biologics and DMPK. He is an adjunct professor at The School of Pharmaceutical Sciences, Sun Yat-Sen University. Prior to joining BioDuro in 2017, Dr. Li worked at Boehringer Ingelheim (BI) for 21 years dedicated to NCE drug discovery in the Immunology & Inflammation, Cardiovascular and Metabolic disease areas, helping to advance multiple compounds into clinical trials. Dr. Li has in-depth expertise in Structure-Based Drug Discovery (SBDD) and Fragment-Based Lead Discovery (FBLD), and is a recipient of a President’s Award for “Fragment-Based Alternate Lead Discovery” at BI. Dr. Li obtained his D.Phil. (1992) from the University of Oxford with Professor Sir C. M. Dobson, FRS FMedSci under a Sino-British Friendship Scholarship, and completed a CRI Postdoctoral Fellowship in General or Cancer Immunology with Professor P.E. Wright (NAS member) at The Scripps Research Institute. He has a BSc from the University of Science and Technology of China (USTC).
President, Global CMC Solutions (China)
Jim Li PhD
President, Global CMC Solutions (China)
Jim Li PhD

Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth, Pfizer and Wuxi Apptec in the area of process research and medicinal chemistry. During his career, he was involved in numerous drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, and diabetes. Dr. Li has co-authored more than 60 research articles and patents.

Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a Postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.

Vice President, Business Development (Asia Pacific)
Lisa Ren
Vice President, Business Development (Asia Pacific)
Lisa Ren

Ms. Lisa Ren has over 16 years of experience in sales, business development and client management across life sciences industries. She joined BioDuro-Sundia in 2012 and has helped the company build a strong customer base and network including pharmaceuticals, biotech, universities, research institutions, government and regulatory agencies. Prior to growing into the role as Vice President of Business Development APAC, Lisa has built up a strong BD team as the Head of Business Development APAC, delivering sales milestone after sales milestone for the company over the past ten years, making great contributions to its outstanding business success.

Prior to joining BioDuro-Sundia, Lisa worked at Fluke Cooperation and Bridge Laboratories for 6 years. She graduated from Beijing Normal University with M.S. degree in Education and B.S degree in Business Management.

Chief Strategy Officer
Roy Xu
Chief Strategy Officer
Roy Xu

Roy has over 25 years of healthcare industry experience. He started his career as an orthopedic surgeon. Roy joined Eli Lilly as a sales rep in 1997. Since then he has had various roles in market research, business intelligence, BU head, strategy, regional general management, business development etc., both at Eli Lilly and Boehringer Ingelheim (BI). Roy also spent more than two years in Germany where he was BI’s Director of Corporate Business and Enabling Strategy.

Roy obtained a bachelor’s degree in Clinical Medicine at Zhejiang Traditional Chinese Medicine University, and an MBA from Zhejiang University.

Vice President, Business Development (Europe)
Michel Blanc
Vice President, Business Development (Europe)
Michel Blanc

Michel Blanc did study organic chemistry and chemical engineering at Ecole Centrale de Marseille in France. He brings over 18 years of experience in servicing Pharmaceutical companies. He held global Business Development responsibilities and was part of the management team at well established Drug Substance and Drug Product CDMOs or APIs producers (Avecia (now part of Piramal), NextPharma, Novasep, Seqens or Pharmazell).

Michel was also a board member of the French fine chemical industry association (SICOS Biochimie) and of the French CDMO association (SPIS now CDMO France).

Chairman
David Preston
Chairman
David Preston

David Preston has had 38 years of healthcare experience with publicly Traded and Private companies in the fields of Pharmaceuticals, Animal Health and Biotechnology as a Board Member. The last 30 years of his experience has been in China, Taiwan and Hong Kong building successful high growth businesses. David Has been Chairman and CEO for Greater China for Sanofi and Boehringer – Ingelheim as well as the Janssen Corporation since 1991 in China. During this time he build high Growth businesses in China through diversified strategies in Innovative Pharmaceuticals. branded Generics. Biotechnology. and Animal Healthcare.

Key highlights in this period included building of the first Westen Multinational Biotechnology C.M.O. facility as well as obtaining the first Test CM.OJ MAHI license. Establishment of a number of High tech Vaccine Plants, and R and D facilities in in the field of Animal Health. Signing and development of numerous JV’s as well as Wholly owned Subsidiaries. Mergers and Acquisitions across Pharmaceutical’s. Animal Health. and Biotechnology industries.

David’s achievement’s in the Healthcare industry and it Growth and development in China is widely recognized By the Chinese Government and the City of Shanghai In 2013 he was awarded the Silver Magnolia allowed in 2015 the Gold Magnolia award. This was then followed by being awarded in 2017 the Honorary Citizen of Shanghai by 40th People’s Municipal Congress of Shanghai. David Holds a Business Science Degree.

Director, Advent Partner
Andrew Li
Director, Advent Partner
Andrew Li

Andrew Li joined Advent in 2012. He previously worked at Warburg Pincus, HSBC PE, Solera Capital and Credit Suisse where he focused on the retail and consumer, healthcare, industrial, and energy sectors. Andrew has worked in finance and private equity throughout the U.S. and China since 1999. Andrew holds a BA from Middlebury College and an MBA from Harvard Business School.

Director, Advent Partner
Michael Miltenberger
Director, Advent Partner
Michael Miltenberger

Michael Miltenberger joined Advent in 2011 as an associate on the healthcare team. Following business school, he rejoined Advent’s Boston office, focusing on healthcare investments. Prior to Advent, Michael was a consultant at McKinsey & Company in their Washington DC office, serving a range of healthcare and private equity clients. Michael earned a BA, cum laude, from Harvard College and an MBA from Harvard Business School, graduating with High Distinction as a Baker Scholar and a Harvey Fellow.

Director, Operating Partner
Masood Tayebi, PhD
Director, Operating Partner
Masood Tayebi, PhD

Dr. Masood Tayebi is the Founder of BioDuro. He currently serves as CEO of a nationwide real estate portfolio and is a Partner and Chief Executive Officer of the Bridgewest Group. Prior to BioDuro, Dr. Tayebi was Co-Founder and Chairman of Wireless Facilities, Inc. (NASDAQ: WFI), a global leader in telecommunications outsourcing.

Director, Operating Partner
Cathy Yen
Director, Operating Partner
Cathy Yen

Cathy joined the Board of Directors of BioDuro-Sundia in 2020, with the Advent-led acquisition of Sundia and creation of BioDuro-Sundia. Prior to that, she was Chairman of the Board at Sundia Meditech Group, where she was the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia solidified its position as one of the leading pre-clinical CROs in China.

Prior to Sundia, Cathy had a distinguished career as a seasoned venture capitalist, having led numerous investments in high-growth companies in Asia. Cathy served as a Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, for over a decade, Vice President at Global Financial Services, Vice President at Crimson Ventures/Chinatrust Bank and Senior Manager at Fortune Capital. She brings over 20 years of experience in corporate finance, accounting, strategic planning and private equity investments.

Director, Operating Partner
Kewen Jin, PhD
Director, Operating Partner
Kewen Jin, PhD
Director, Operating Partner
Amit Patel
Director, Operating Partner
Amit Patel

Amit Patel has twenty years of healthcare industry experience with publicly-traded, private equity-backed, and start-up companies in the capacity of executive, board member, advisor, and investor. He is currently Executive Chairman of Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company) and a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma. Recently, Amit was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017).

Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc. as EVP & Head of North America, and SVP & Head of Global Corporate Development & Strategic Planning. Earlier, Amit was VP of Corporate Development at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS). He started his career as a strategy consultant with Marakon Associates. Amit holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania.

Our History
We went through multiple successful integrations and have embarked on the next phase of growth to deliver more value to customers
2021

Acquired two US-based commercial drug product manufacturing facilities with over 100,000 sq. ft. and 4 billion doses capacity annually

Completed 1st GMP drug product manufacturing at new R&D center in Wuxi

2020

Acquired Sundia to become BioDuro-Sundia, one of the largest CRDMOs worldwide

300,000 sq. ft. Wuxi facility opened with integrated capabilities across discovery and GMP manufacturing

2019

Advent bought majority of stake and partnered with BioDuro

2018

Acquired Molecular Response (“Tumor Bank”)

2015

BioDuro reacquired from PPD; BioDuro and Formex merged to enable broad range of service offering

2013

Formex joined Bridgewest Group, operating in a 44,000 sq. ft. GMP facility

2012

93,000 sq. ft. Shanghai facility (72,000 sq. ft. lab) opened to meet growing client demand

2009

BioDuro acquired by PPD

2007

Sundia merged with United Pharma

2006

100,000 sq. ft. Beijing site opened –first site in China

2005

BioDuro founded in San Diego by Biotech Investment Group with operations commenced in Beijing

2004

Sundia founded

1996

Formex formed

Business Ethics
Business Conduct and Ethics

At BioDuro-Sundia, we operate with integrity and strict standards of law and business ethics, which are our fundamental guidelines in all locations. We adhere the business ethics of legal compliance, integrity and self-discipline, and strictly comply with laws and regulations related to corporate governance and the Corporate Governance Code, and have zero tolerance for any form of corruption. We have built a strong security infrastructure that protects and preserves the intellectual property and data of our customers; We are implementing green manufacturing and sustainable operations across our business units, helping to improve the environment and our communities.

Learn more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all